<DOC>
	<DOCNO>NCT00469092</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , Oceania South America . This trial aim comparison biphasic insulin aspart 30 daily versus insulin glargine daily combination metformin glimepiride insulin naive subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Biphasic Insulin Aspart 30 Versus Insulin Glargine Both Combination With Metformin Glimepiride Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Treatment OADs ( Oral AntiDiabetic Drugs ) 6 month Ongoing stable treatment metformin least 2 month Ongoing stable treatment minimum half maximal dose insulin secretagogue least 2 month Insulin naive HbA1c ( glycosylated haemoglobin A1c ) 7.0 % 11.0 % ( inclusive value ) Metformin contraindication accord local practice TZD ( thiazolidinedione ) treatment last 5 month trial start Systemic treatment corticosteroid 3 month trial start Any disease condition accord Investigator would interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>